Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
A judge at the US District Court for the District of Delaware has issued a preliminary injunction against CryoLife, finding that the medical device maker’s PerClot Topical haemostatic powder infringes rival company C R Bard’s patent.   12 March 2015
Americas
In the battle for marketing approval of a biosimilar version of Neupogen under the BPCIA, applicant Sandoz stymied Amgen’s chance to join the so-called patent dance. Andrew Williams of McDonnell Boehnen Hulbert & Berghoff ponders the implications.   12 March 2015
Americas
Japanese company Otsuka Pharmaceutical has sued drugs company Wockhardt for patent infringement at the US District Court for the District of New Jersey.   11 March 2015
Americas
Pharmaceutical company Janssen has sued drugs businesses Celltrion and Hospira in one of the first patent infringement actions brought under the Biologics Price Competition and Innovation Act.   10 March 2015
Americas
The US Supreme Court yesterday refused to hear a case between Californian pharmaceutical company Gilead and India-based Natco that concerns ‘double patenting’.   10 March 2015
Big Pharma
The German Court of Appeal has ruled that Indianapolis-based Eli Lilly’s European “vitamin regimen” patent for lung cancer injection Alimta would not be infringed by Actavis’s generic version.   9 March 2015
Americas
The US Food and Drug Administration approved Sandoz’s cancer product Zarxio on Friday—the first biosimilar to be rubber stamped in the US.   9 March 2015
Asia
As India appears to forge closer trade relations with the US, will the country introduce a data exclusivity legal provision and what impact would this have? LSIPR investigates.   5 March 2015
Americas
Law firm Fried, Frank, Harris, Shriver & Jacobson has added a life sciences specialist to its intellectual property litigation practice.   5 March 2015
Americas
The US Patent and Trademark Office’s Patent Trial and Appeal Board has handed down what are thought to be the first written decisions in inter partes review proceedings that concern the biopharmaceutical industry.   5 March 2015